Lipocine (STU:2VT0) Total Stockholders Equity: €18.89 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2VT0 Lipocine Inc STU:2VT0
47 GF Score
Price €3.94
GF Value €2.43
! 4 Warning Signs
View Full Analysis

What is Lipocine Total Stockholders Equity?

Lipocine STU:2VT0 47 Total Stockholders Equity is €18.89 Mil as of Jun. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 47/100 and a GF Value™ of €2.43. The stock has 4 warning signs investors should review.

Lipocine's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €18.89 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Lipocine's Book Value per Share for the quarter that ended in Jun. 2026 was €2.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Lipocine's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Lipocine  (STU:2VT0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Lipocine's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(18.894-0)/7.475
=2.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Lipocine's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 18.894
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Total Stockholders Equity Related Terms

Lipocine Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Lipocine's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Total Stockholders Equity Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.33 33.64 18.68 20.05 12.36

Lipocine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.85 12.05 12.36 19.75 18.89
STU:2VT0
47GF Score
Lipocine Inc STU:2VT0
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €18.89 Mil mean?
Lipocine (STU:2VT0) has a Total Stockholders Equity of €18.89 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Lipocine and its competitors.
Is Lipocine's Total Stockholders Equity too high?
Lipocine's current Total Stockholders Equity is €18.89 Mil. Overall, Lipocine has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Total Stockholders Equity compare to NXTC and VYNE?
Lipocine's Total Stockholders Equity of €18.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Lipocine and its competitors. Lipocine's current Total Stockholders Equity is €18.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Total Stockholders Equity of €18.89 Mil. The stock's GF Value™ is €2.43, compared to a current price of €3.94 — trading 62.3% above its estimated fair value. The current Total Stockholders Equity is €18.89 Mil. Lipocine's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Total Stockholders Equity is €18.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 62.3% above its estimated GF Value™ of €2.43.

Key valuation signals for STU:2VT0:

  • Total Stockholders Equity: €18.89 Mil
  • GF Value™: €2.43 vs. price of €3.94 (62.3% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
47GF Score

Get the complete analysis for STU:2VT0

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€2.43
GF Value